investor.regeneron.comInvestor Relations | Regeneron Pharmaceuticals Inc.
investor.regeneron.com Profile
Investor.regeneron.com is a subdomain of regeneron.com,
which was created on 1997-07-10,making it 27 years ago.
It has several subdomains, such as careers.regeneron.com
clinicaltrials.regeneron.com , among others.
Description：The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial...
Discover investor.regeneron.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
investor.regeneron.com Information
| HomePage size: 94.184 KB |
| Page Load Time: 0.199735 Seconds |
| Website IP Address: 184.50.88.74 |
investor.regeneron.com Similar Website
| Masonite International Corp. - Investor Relations - Investor Relations |
| Investor Relations | Regeneron Pharmaceuticals Inc. |
| Block, Inc. (SQ) Investor Relations - Investor Relations |
| Gen Investor Relations - Investor Relations |
| MindChamps PreSchool Limited - Investor Relations: Investor Relations |
| Home - Ayala Land Investor Relations : Ayala Land Investor Relations |
| Universal Technical Institute's Investor Relations - UTI Investor Relations |
| Ameriprise Financial Investor Relations | Investor Relations |
| Meridian Bank Investor Relations - Meridian Bank Investor Relations |
| Armstrong World Industries Investor Relations | Armstrong Flooring Investor Relations |
| Walmart Investor Relations - Investor Relations |
investor.regeneron.com PopUrls
| Investor Relations | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/ |
| investors & media - | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/node/ |
| 2021 Responsibility Report https://investor.regeneron.com/2021RR |
| 2020 RESPONSIBILITY REPORT https://investor.regeneron.com/2020RR |
| Regeneron / 2019 Responsibility Report https://investor.regeneron.com/2019RR |
| 0001104659-23-107161 | 8-K | XBRL Viewer https://investor.regeneron.com/node/28561/xbrl-viewer |
| 0001104659-22-002403 | 8-K | iXBRL Viewer https://investor.regeneron.com/node/26201/ixbrl-viewer |
| 0000930413-20-000068 | 8-K | iXBRL Viewer https://investor.regeneron.com/node/23151/ixbrl-viewer |
| 0001104659-23-099351 | 8-K/A | XBRL Viewer https://investor.regeneron.com/node/28451/xbrl-viewer |
| Events & Presentations | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/events-and-presentations |
| Press Releases | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/press-releases |
| Stock Information | Regeneron Pharmaceuticals Inc. https://investor.regeneron.com/stock-information |
| Regeneron Reports Fourth Quarter and Full Year 2023 Financial and ... https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2023-financial |
| Regeneron Reports First Quarter 2024 Financial and Operating Results ... https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-first-quarter-2024-financial-and-operating |
| Regeneron Reports Fourth Quarter and Full Year 2021 Financial and ... https://investor.regeneron.com/news-releases/news-release-details/regeneron-reports-fourth-quarter-and-full-year-2021-financial |
investor.regeneron.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Security-Policy: report-uri //report-csp-violation |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1581762537" |
| From-Origin: same |
| Last-Modified: Sat, 15 Feb 2020 10:28:57 GMT |
| Link: http://investor.regeneron.com/; rel="shortlink", https://investor.regeneron.com/investor-relations/; rel="canonical", https://investor.regeneron.com/investor-relations; rel="alternate"; hreflang="en", https://investor.regeneron.com/investor-relations; rel="revision", https://investor.regeneron.com/investor-relations; rel="revision" |
| Server: nginx |
| X-Age: 188 |
| X-Cache-Hits: 1 |
| X-Content-Security-Policy: report-uri //report-csp-violation |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-f92d6cee-4fdd-11ea-bd14-dfe3d9acd4c4 |
| X-UA-Compatible: IE=edge |
| X-WebKit-CSP: report-uri //report-csp-violation |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 15406 |
| X-EdgeConnect-MidMile-RTT: 42, 42 |
| X-EdgeConnect-Origin-MEX-Latency: 29, 29 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Sat, 15 Feb 2020 10:32:06 GMT |
| Date: Sat, 15 Feb 2020 10:32:06 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: DrupalVisitorMobile=0; path=/ |
| Strict-Transport-Security: max-age=15768000 ; preload |
investor.regeneron.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | Regeneron Pharmaceuticals Inc." name="title"/ |
| content="Regeneron Pharmaceuticals Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts." name="description"/ |
| content="https://investor.regeneron.com/investor-relations" property="og:url"/ |
| content="Investor Relations | Regeneron Pharmaceuticals Inc." property="og:title"/ |
| content="no-referrer" name="referrer"/ |
| content="The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial analysts." property="og:description"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
investor.regeneron.com Ip Information
| Ip Country: United States |
| City Name: San Jose |
| Latitude: 37.1835 |
| Longitude: -121.7714 |
investor.regeneron.com Html To Plain Text
Scientists Patients Medical Professionals Investors & Media Careers About Leadership History Collaborations Industrial Operations Locations Science Pipeline Research Areas Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST® ( rilonacept ) INJECTION DUPIXENT® ( dupilumab ) INJECTION EYLEA® ( aflibercept ) INJECTION KEVZARA® ( sarilumab ) INJECTION LIBTAYO® ( cemiplimab-rwlc) INJECTION PRALUENT® ( alirocumab ) INJECTION Citizenship Science Education Science Talent Search Sustainable Communities Supporting Patients Culture of Integrity Grants Investors & Media Careers Scientists Patients Medical Professionals Contact Us Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. Read on Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health. Read on Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body’s most complex mysteries. Read on In addition to our work to invent new and needed medicines, we are focused on improving our world and operating with the highest standards of integrity. We are proud not only of what we do, but how we do it. Read on Investor Relations About Leadership History Collaborations Industrial Operations Locations Science Pipeline Research Areas Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST ® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc) INJECTION PRALUENT® ( alirocumab ) Injection Citizenship Science Education Science Talent Search Sustainable Communities Supporting Patients Culture of Integrity Grants Investors & Media News Events Stock Information Financial Information Corporate Governance FAQs Careers Scientists Patients Medical Professionals Contact Us INVESTORS & MEDIA INVESTORS & MEDIA Investor Relations News Events Stock Information Financial Information Corporate Governance FAQs We are a leading science and technology company that delivers life-transforming medicines for serious diseases. Founded by physician-scientists more than 30 years ago, our science-driven approach has resulted in seven FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases. In addition to our medicines, our innovations include the VelociSuite ® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good. Investor Relations High Low Volume Market Cap 02/15/20 5:28 AM EST Copyright West LLC. Minimum 15 minutes delayed. 3 mo. 6 mo. 1 yr. Stock information Financial information 3 mo. 6 mo. 1 yr. Stock information Financial information NEWSROOM Feb 12 Regeneron Announces Upcoming Investor Conference Presentations Read on Feb 08 EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy Read on EVENTS Events Barclays Global Healthcare Conference Mar 10 4:50 PM EDT Mar 10, 2020 | 4:50 PM EDT Cowen 40th Annual Healthcare Conference Mar 2 1:30 PM EST Mar 2, 2020 | 1:30 PM EST listen to webcast SVB Leerink 9th Annual Global Healthcare Conference Feb 25 10:00 AM EST Feb 25, 2020 | 10:00 AM EST listen to webcast Events & Presentations Investor Relations High Low Volume Market Cap 02/15/20 5:28 AM EST Copyright West LLC. Minimum 15 minutes delayed. 3 mo. 6 mo. 1 yr. Stock information Financial information Investor Relations 914.847.7741 invest@regeneron.com Media Relations media@regeneron.com Investor email alerts Download Center Add Files 2019 Form 10-K 2.5 MB Add Files 2018 Responsibility Report 8.5 MB Add Files 2018 Annual Report 3.7 MB Add Files 2019 Proxy Statement 8.2 MB Add Files Senior Management Biographies 3.3 MB Add Files Corporate Fact Sheet 2 MB Add Files Regeneron Genetics Center Backgrounder 1.9 MB Investor Relations 914.847.7741 invest@regeneron.com Media Relations media@regeneron.com Investor email alerts Email Alerts Email Alerts RSS RSS Print Print Share Share Search Search Facebook Google LinkedIn Twitter RSS About Leadership History Collaborations Industrial Operations Locations Science Pipeline Research Areas Technology Regeneron Genetics Center Scientific Publications Medicines ARCALYST® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc ) Injection PRALUENT® ( alirocumab ) Injection Citizenship Science Education Science Talent Search Sustainable Communities Supporting Patients Culture of Integrity Grants Investors & Media Careers Scientists Patients Medical Professionals Contact Us Terms of Use Privacy Policy Social Media Terms of Engagement Ireland Site Contact Us CAREERS Join our team and help turn science into life-changing medicine. Column 1 Investors & Media News Events Stock Information Financial Information Corporate Governance FAQs Patients Medical Professionals Scientists Column 2 About Leadership History Collaborations Industrial Operations Locations Science Pipeline Research Areas Technology Regeneron Genetics Center Scientific Publications Column 3 Medicines ARCALYST® ( rilonacept ) Injection DUPIXENT® ( dupilumab ) Injection EYLEA® ( aflibercept ) Injection KEVZARA® ( sarilumab ) Injection LIBTAYO® ( cemiplimab-rwlc ) Injection PRALUENT® ( alirocumab ) Injection Citizenship Science Education The Regeneron Science Talent Search Sustainable Communities Supporting Patients Culture of Integrity...
investor.regeneron.com Whois
Domain Name: REGENERON.COM Registry Domain ID: 637549_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2023-05-10T06:42:45Z Creation Date: 1997-07-10T04:00:00Z Registry Expiry Date: 2028-07-09T04:00:00Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: domain.operations@web.com Registrar Abuse Contact Phone: +1.8777228662 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS11.WORLDNIC.COM Name Server: NS12.WORLDNIC.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T14:08:23Z <<<